ArticleMetabolic engineering communications2020
Development of both type I-B and type II CRISPR/Cas genome editing systems in the cellulolytic bacterium
Article in Metabolic engineering communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 103 citations in OpenAlex.
- Target discrimination and PAM profiling of the Thermotoga maritima type I-B CRISPR system.The Biochemical journal · 2026Article
- Molecular adaptations and engineering of extremophiles for synthetic biology and biotechnological applications.Frontiers in microbiology · 2026Review
- A thermostable Cas9-based genome editing system for thermophilic acetogenic bacteriumApplied and environmental microbiology · 2025Article
- Hi-TARGET: a fast, efficient and versatile CRISPR type I-B genome editing tool for the thermophilic acetogen Thermoanaerobacter kivui.Biotechnology for biofuels and bioproducts · 2025Article
- A diverse single-stranded DNA-annealing protein library enables efficient genome editing across bacterial phyla.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Harnessing the Streptomyces-originating type I-E CRISPR/Cas system for efficient genome editing in Streptomyces.Science China. Life sciences · 2025Article
- Thermophilic site-specific recombination system for rapid insertion of heterologous DNA into the Clostridium thermocellum chromosome.Journal of industrial microbiology & biotechnology · 2024Article
- Current models in bacterial hemicellulase-encoding gene regulation.Applied microbiology and biotechnology · 2024Review
- Biofuel production from lignocellulose via thermophile-based consolidated bioprocessing.Engineering microbiology · 2024Review
- A highly efficient method for genomic deletion across diverse lengths in thermophilicSynthetic and systems biotechnology · 2024Article
- Research Progress on the Mechanism and Application of the Type I CRISPR-Cas System.International journal of molecular sciences · 2024Review
- Research advances on the consolidated bioprocessing of lignocellulosic biomass.Engineering microbiology · 2024Review
- Application of functional genomics for domestication of novel non-model microbes.Journal of industrial microbiology & biotechnology · 2024Review
- The potential of native and engineered Clostridia for biomass biorefining.Frontiers in bioengineering and biotechnology · 2024Review
- A type I-F CRISPRi system unveils the novel role of CzcR in modulating multidrug resistance ofMicrobiology spectrum · 2023Article
- A thermostable type I-B CRISPR-Cas system for orthogonal and multiplexed genetic engineering.Nature communications · 2023Article
- Ethanol tolerance in engineered strains of Clostridium thermocellum.Biotechnology for biofuels and bioproducts · 2023Article
- Metabolic engineering of Thermoanaerobacterium AK17 for increased ethanol production in seaweed hydrolysate.Biotechnology for biofuels and bioproducts · 2023Article
- Type I CRISPR-Cas-mediated microbial gene editing and regulation.AIMS microbiology · 2023Review
- Endogenous CRISPR/Cas systems for genome engineering in the acetogensFrontiers in bioengineering and biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The robust lignocellulose-solubilizing activity of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.